{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-229173","form_type":"8-K","ticker":"CGEM","cik":"0001789972","company_name":"Cullinan Therapeutics, Inc.","filed_at":"2026-05-18T21:30:08+00:00","discovered_at":"2026-05-18T21:32:00.303660+00:00","generated_at":"2026-05-18T21:32:59.253719+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Cullinan reports initial Phase 1 data for CLN-978: B cell depletion and early efficacy in RA/SLE","bullets":["As of Jan 14, 2026 cutoff, 14 patients dosed (5 RA, 9 SLE) across cohorts 1-3.","B cell depletion >75% in 9/11 patients after 10 mcg; 3/6 below quantification after 20 mcg.","4/5 RA patients had DAS28-ESR decrease from high activity to moderate/remission.","5/6 SLE patients had SLEDAI score decrease >4 points; ultrasound synovitis improved in 3/4 RA.","CLN-978 well tolerated; dose escalation continues; updated data at EULAR June 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-229173","json":"https://secwatch.observer/filing/0001193125-26-229173.json","markdown":"https://secwatch.observer/filing/0001193125-26-229173.md","text":"https://secwatch.observer/filing/0001193125-26-229173.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789972/000119312526229173/0001193125-26-229173-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789972/000119312526229173/cgem-20260518.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T21:32:59.253719+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}